期刊文献+

c-erbB-2基因表达与乳腺癌关系的研究 被引量:2

EXPRESSION OF C-ERBB-2,P52 AND PCNA IN BREAST CANCER
下载PDF
导出
摘要 目的:探讨乳腺癌组织c-erbB-2 mRNA与蛋白表达之间的关系,从而明确c-erbB-2基因mRNA转录和蛋白表达在乳腺癌演化过程中的意义。方法:建立LightCycler实时RT-PCR方法,检测38例乳腺癌、17例癌旁组织、10例乳腺腺病组织c-erbB-2 mRNA的表达情况;用免疫组化SP法检测以上38例乳腺癌患者c-erbB-2表达情况。结果:乳腺癌组c-erbB-2 mRNA的表达水平明显高于其他两组(均为P<0.001)。c-erbB-2 mRNA表达水平与蛋白表达水平相关(P<0.05)。结论:c-erbB-2 mRNA表达水平的检测有助于乳腺癌的诊断。 Objective: To establish the real time RT- PCR method to measure the expression of c - erbB - 2 mRNA in breast cancer, tissues of beside tumors and tissues of adenosis of mammary glands, to find out the relationship of c- erbB-2 protein with its mRNA. Methods: The real time RT-PCR method for detecting the expression of c- erbB-2 was established successfully. 38 specimens of breast cancer, 17 of beside tumors, 10 of adenosis of mammary glands were detected. Antibodies against c - erbB-2, P53 and PCNA were evaluated by IHC technique for the 38 specimens of breast cancer. Results: There is significant difference in the level of c- erbB-2 mRNA among the three groups (P〈0.05). The level of c- erbB- 2 mRNA has correlation with the c- erbB-2 protein (P〈0.05). Conclusion: Detection of c- erbB-2 mRNA can hdp diagnose breast cancer.
出处 《现代预防医学》 CAS 北大核心 2006年第12期2302-2303,共2页 Modern Preventive Medicine
关键词 C-ERBB-2 乳腺癌 IHC 实时RT-PCR c-erbB-2 Breast cancer IHC Real time RT-PCR
  • 相关文献

参考文献3

二级参考文献49

  • 1[1]Hung MC, Lau YK. Basic science of HER-2/neu: a review[J]. Semin Oncol, 1999, 26 (4suppl 12): 51-59.
  • 2[2]Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer[J]. Oncogene, 2000,19(53):6102-6114.
  • 3[3]Ross JS, Fletcher JA. The Her-2/neu oncogene: prognostic factor. Predictive factor and target for therapy [J].Semin Cancer Biol, 1999,9(2): 125-138.
  • 4[4]Slamon DJ, Clark GM,Wong SG,et al. Human breast cancer.correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science, 1987,235(4785): 177-182.
  • 5[5]Cooke T, Reeves J, Lannigan A, et al. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic maker [J]. Eur J Cance,2001,37 (suppl 1):S3-S10.
  • 6[6]Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence if in situ carcinoma[J]. J Clin Oncol, 1992,10(4): 599-605.
  • 7[7]Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer [J]. J Clin Oncol, 1992,10(7):1049-1056.
  • 8[8]Hamilton A,Piccart M.The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2[J]. Ann Oncol, 2000,11(6):647-663.
  • 9[9]Baselga J, Seidman AD, Rosen PP, et al. HER2 overexprcssion and paclitaxel sensitivity in breast cancer: therapeutic implications[J]. Oncology, 1997,11(3suppl 2):43-48.
  • 10[10]Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer[J]. Semin Oncol, 2000,27(6suppl 11):46-52.

共引文献28

同被引文献64

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部